ArticleResearch square2026
Direct Coronary Vascular and Lipidomic Remodeling by Low-Dose GLP-1 Agonist Therapy in Cardiometabolic HFpEF.
Article in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) reduce major adverse cardiovascular events in patients with type 2 diabetes and obesity[1, 2], but the mechanisms underlying these benefits remain incompletely defined. Although GLP-1RAs improve vascular function[3] and alter circulating lipid species associated with cardiovascular risk [4-6], whether these effects extend to diseased coronary vessels and occur independently of weight loss is unknown. Here, we show that weight-neutral semaglutide administration in two complementary cardiometabolic HFpEF models - a porcine model of metabolic syndrome with coronary artery disease and the ZSF-1 obese HFpEF rat - improves coronary and aortic endothelium-dependent vasodilation, attenuates coronary vascular remodeling and fibrosis, increases myocardial microvascular density, and remodels the plasma lipidome through reductions in ceramides and diacylglycerols together with enrichment of long-chain polyunsaturated triacylglycerols. These findings identify direct vascular and metabolic actions of semaglutide that are independent of weight loss.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.